Molecular Switch in Pancreatic Cancer Offers New Treatment Hope

Researchers have identified a crucial molecular mechanism governing how pancreatic cancer cells develop resistance to chemotherapy, potentially paving the way for more effective treatment strategies. The discovery, led by scientists at Duke-NUS Medical School, centers on a gene called GATA6 and its interaction with the KRAS/ERK pathway.

Why Pancreatic Cancer Is So Tricky to Treat

Pancreatic cancer is a particularly deadly form of cancer, ranking as the fourth leading cause of cancer-related death in Singapore despite being the ninth most common cancer diagnosed ¹. Its aggressive nature, late diagnosis, and limited responsiveness to conventional therapies contribute to its poor prognosis. Chemotherapy remains a mainstay of treatment, but often provides only modest benefits.

Two Subtypes of Pancreatic Cancer: Classical and Basal

Over the past decade, research has revealed two primary molecular subtypes of pancreatic cancer: classical and basal ³. Classical tumors exhibit a more organized cellular structure and tend to respond better to treatment. Conversely, basal subtype tumors are more disorganized, aggressive, and often resistant to chemotherapy. Importantly, cancer cells can transition between these subtypes, shifting from a treatable state to a resistant one – a phenomenon known as cancer cell plasticity.

The Role of GATA6 in Treatment Response

The research team focused on the gene GATA6, which plays a key role in maintaining the more structured and less aggressive classical state of pancreatic cancer cells. High levels of GATA6 are associated with better organization and increased sensitivity to chemotherapy. When GATA6 levels decline, cells lose their structure, become more aggressive, and are harder to treat ¹.

KRAS and ERK Pathway Suppress GATA6

The study revealed that the KRAS/ERK pathway suppresses GATA6. KRAS, a gene mutated in nearly all pancreatic cancers, drives tumor growth. When the ERK pathway is highly active, it interferes with GATA6 production. Blocking the KRAS and ERK pathway allows GATA6 levels to rebound, shifting cancer cells back toward the more organized, chemotherapy-sensitive state ².

Combination Therapy Shows Promise

The researchers found that combining drugs that inhibit the KRAS and ERK pathway with standard chemotherapy resulted in stronger anti-cancer effects than either approach alone. This enhanced benefit was observed only when GATA6 was present, underscoring its critical role in determining treatment response ¹.

Implications for Other KRAS-Driven Cancers

The implications of this research extend beyond pancreatic cancer. Many other cancers are driven by KRAS mutations and exhibit similar shifts in cell behavior and treatment response. Understanding how cancer cells transition between different states could lead to new strategies for overcoming therapy resistance in a wider range of cancers ¹.

Future Directions

These findings provide a mechanistic explanation for why pancreatic tumors respond poorly to chemotherapy and offer a rational strategy for combining targeted therapies with existing drugs. Ongoing clinical trials are testing new treatments aimed at KRAS and related pathways, building on this foundational research. Understanding how cancer cells switch states provides a more strategic approach to designing effective combination treatments.